The Game Changer in the management of Diabetic Gastroparesis

Medagut is a Unique, patented formulation based on micronization technology derived from Pistacia lentiscus gum (Mastic gum) — a natural resin known for its anti-inflammatory, antioxidant, and gastro-protective properties.

Category:

Description

The product is based on a unique patented technology enhancing the overall bioavailability of the product by 3-4 four folds with the help of micronzation technology based on polymers.
Mechanism of Action in Diabetic Gastroparesis

1. Gastro-protective & Anti-inflammatory Modulation (Mucosal Healing & TNF-α / IL-6 Suppression)
o Mastic gum exhibits strong anti-inflammatory action by inhibiting pro-inflammatory cytokines such as TNF-α, IL-6, and NF-κB, which are elevated in diabetic gastric neuropathy and delayed gastric emptying.
o It promotes mucosal regeneration and reduces oxidative stress-induced gastric damage, improving gastric lining health and motility.

2. Pro=kinetic Action via Enteric Nervous System Modulation
o Bioactive terpenoids in pistacia gum stimulate acetylcholine release and enhance interstitial cells of Cajal (ICC) pacemaker activity, improving gastric peristalsis.
o It also upregulates ghrelin and motilin secretion, thereby enhancing gastric emptying and reducing gastric retention time.

 3. Antioxidant & Neuro-protective Effect Against Diabetic Autonomic Neuropathy
o Chronic hyperglycemia in diabetes causes autonomic neuropathy, leading to gastroparesis.
o Mastic gum scavenges reactive oxygen species (ROS), increases superoxide dismutase (SOD) and glutathione (GSH) levels, protecting vagal and enteric neurons, thereby preserving neuromuscular coordination of the stomach.

4. Clinical and Preclinical Evidence
Preclinical Studies
• Animal models demonstrated a 45–60% improvement in gastric emptying time compared to controls.
• Histopathological analysis revealed significant mucosal healing and reduction in oxidative markers.
Clinical Pilot Study (Medarmi Biophar Internal Data, 2024)
• Participants: 120 patients with diabetic gastroparesis.
• Duration: 12 weeks.
• Outcome Measures: Gastric emptying rate, symptom score, glycaemic stability.
Results:
o 78% improvement in gastric emptying rate.
o 70% reduction in nausea and bloating scores.
o 25% improvement in HbA1c control due to improved digestion and meal tolerance.
o No serious adverse events reported.